XML 90 R77.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Recognition - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation Of Revenue [Line Items]          
Payment period from distributors received from date of sale     45 days    
Net loss per share basic [1]     $ (0.2) $ (0.15) $ (0.26)
Net loss per share-diluted [1]     $ (0.20) $ (0.15) $ (0.26)
Effect of significant financing component when transfer and customer payment of good or service occurs within one year or less     true    
Medicaid rebate          
Disaggregation Of Revenue [Line Items]          
Change in estimate recognized       $ 15.1  
Change in net income loss       $ 15.1  
Net loss per share basic       $ (0.18)  
Net loss per share-diluted       (0.18)  
Exclusion of licensing revenue change in estimate          
Disaggregation Of Revenue [Line Items]          
Net loss per share basic     $ (0.21) (0.17)  
Net loss per share-diluted     $ (0.21) $ (0.17)  
VASCEPA 1-Gram          
Disaggregation Of Revenue [Line Items]          
Product expiration date after being converted into capsule form     4 years    
VASCEPA 0.5-Gram          
Disaggregation Of Revenue [Line Items]          
Product expiration date after being converted into capsule form     3 years    
Edding          
Disaggregation Of Revenue [Line Items]          
Adjusted measure of performance and additional license revenue recognized $ 4.0 $ 5.0      
HLS          
Disaggregation Of Revenue [Line Items]          
Adjusted measure of performance and additional license revenue recognized   $ 5.3      
Minimum          
Disaggregation Of Revenue [Line Items]          
Sales discount percentage     2.00%    
Maximum          
Disaggregation Of Revenue [Line Items]          
Sales discount percentage     3.00%    
[1] Excluding the licensing revenue change in estimate incurred in 2024 and the licensing revenue change in estimate and Medicaid change in estimate incurred in 2023, both discussed in Note 12 – Revenue Recognition, net loss per share basic and diluted for both years ended December 31, 2024 and 2023 would have been $(0.21).